Patents Assigned to DermBiont, Inc.
  • Compositions and formulations for use of a PK inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders
    Patent number: 12290506
    Abstract: Provided herein are compositions comprising ruboxistaurin free base and its salts thereof and methods of use for treating conditions of the skin.
    Type: Grant
    Filed: April 1, 2024
    Date of Patent: May 6, 2025
    Assignee: DermBiont, Inc.
    Inventors: Emma Taylor, Karl Beutner, Christopher Phillips, Mark De Souza, Ravi Kumar Pandrapragada, Vanessa Alexandra Cofré Urrutia, Brendan Philip Brady, Charles Rodney Greenaway Evans
  • Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
    Patent number: 12064459
    Abstract: Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: August 20, 2024
    Assignee: DermBiont, Inc.
    Inventors: Robert M. Brucker, Xuecheng Zhang, Ida Lister, Sanjay Jain
  • Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
    Patent number: 11040077
    Abstract: Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: June 22, 2021
    Assignee: DermBiont, Inc.
    Inventors: Robert M. Brucker, Xuecheng Zhang, Ida Lister, Sanjay Jain